Technical Analysis for ZGNX - Zogenix, Inc.

Grade Last Price % Change Price Change
grade F 37.39 0.48% 0.18
ZGNX closed up 0.48 percent on Tuesday, April 23, 2019, on 1.19 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical ZGNX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 0.48%
Wide Bands Range Expansion 0.48%
Oversold Stochastic Weakness 0.48%
Wide Bands Range Expansion 3.37%
Down 3 Days in a Row Weakness 3.37%
Down 4 Days in a Row Weakness 3.37%
Down 5 Days in a Row Weakness 3.37%
Oversold Stochastic Weakness 3.37%

Older signals for ZGNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Chemistry Pharmaceutical Pain Schizophrenia Central Nervous System Disorders Morphinans Cell Signaling European Union Neurochemistry Ketones Migraine Bipolar Disorder Hydrocodone Severe Chronic Pain Treatment Of Central Nervous System Disorders Treatment Of Migraine Indoles Retail Pharmacies Triptans
Is ZGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 62.75
52 Week Low 33.43
Average Volume 819,889
200-Day Moving Average 46.2823
50-Day Moving Average 48.754
20-Day Moving Average 45.79
10-Day Moving Average 38.084
Average True Range 2.3249
ADX 51.19
+DI 9.9577
-DI 39.4654
Chandelier Exit (Long, 3 ATRs ) 49.5253
Chandelier Exit (Short, 3 ATRs ) 42.2247
Upper Bollinger Band 61.4087
Lower Bollinger Band 30.1713
Percent B (%b) 0.23
BandWidth 68.218825
MACD Line -4.0155
MACD Signal Line -2.9519
MACD Histogram -1.0636
Fundamentals Value
Market Cap 928.8 Million
Num Shares 24.8 Million
EPS -3.42
Price-to-Earnings (P/E) Ratio -10.93
Price-to-Sales 35.07
Price-to-Book 12.08
PEG Ratio -0.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.96
Resistance 3 (R3) 39.82 38.84 39.53
Resistance 2 (R2) 38.84 38.18 38.90 39.38
Resistance 1 (R1) 38.11 37.78 38.48 38.25 39.24
Pivot Point 37.13 37.13 37.31 37.19 37.13
Support 1 (S1) 36.40 36.47 36.77 36.54 35.54
Support 2 (S2) 35.42 36.07 35.48 35.40
Support 3 (S3) 34.69 35.42 35.25
Support 4 (S4) 34.83